The main objective of the ANACONDA-COVID-19 trial is to assess the efficacy of Anakinra +
optimized Standard of Care (oSOC) as compared to oSOC alone on the condition of patients with
COVID-19 infection and worsening respiratory symptoms. Success defined as patient alive and
free of invasive mechanical ventilation (IMV) and free of Extracorporeal Membrane Oxygenation
(ECMO) at Day 14.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Tours
Collaborators:
INSERM CIC-P 1415, University Hospital Center of Tours Swedish Orphan Biovitrum Swedish Orphan Biovitrum (SOBI)